Piperacilina/tazobactam en el sistema VITEK ®2 Piperacillin / Tazobactam in the VITEk ®2 System

Piperacilina/tazobactam en el sistema VITEK ®2 Piperacillin / Tazobactam in the VITEk ®2 System

Bibliographic Details
Main Authors:	Javier Gutman, Giovanna Matiz
Format:	Article
Language:	English
Published:	Asociación Colombiana de Infectología 2011-06-01
Series:	Infectio
Online Access:	http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0123-93922011000200009

Similar Items

Piperacillin/Tazobactam (ZOSYN)
by: Stephanie M. Culver, et al.
Published: (1996-01-01)

Piperacillin–tazobactam as alternative to carbapenems for ICU patients
by: Benoit Pilmis, et al.
Published: (2017-11-01)

Piperacillin/Tazobactam as Cause of Acute Generalized Exanthematous Pustulosis
by: Aikaterini Kyriakou, et al.
Published: (2019-01-01)

Piperacillin/Tazobactam-Induced Neutropenia: A Case Report
by: Hayati DEMİRASLAN, et al.
Published: (2012-03-01)

Results of the effectiveness of two piperacillin–tazobactam molecules in the real world
by: Jorge Enrique Machado-Alba, et al.
Published: (2018-11-01)

<i>Enterobacter </i>endophthalmitis: Treatment with intravitreal tazobactam- piperacillin
by: Singh Trehan, et al.
Published: (2007-01-01)

Galactomannan detection from piperacillin-tazobactam brands available in the Brazilian market
by: Melissa Orzechowski Xavier, et al.

In Vitro Synergy of Levofloxacin Plus Piperacillin/Tazobactam against Pseudomonas aeruginosa
by: Vladimir Chachanidze, et al.
Published: (2009-01-01)

Impact on Bacterial Resistance of Therapeutically Nonequivalent Generics: The Case of Piperacillin-Tazobactam.
by: Carlos A Rodriguez, et al.
Published: (2016-01-01)

Evaluation of Implementation of Extended-Infusion Piperacillin-Tazobactam at an Academic Medical Center
by: Radosevich, John, et al.
Published: (2011)

Trombocitopenia Severa Induzida Por Piperacilina/Tazobactam: A Propósito de Um Caso Clínico
by: Sara Montezinho, et al.
Published: (2021-03-01)

The potential of meropenem and piperacillin-tazobactam combination to Acinetobacter spp clinical isolates in vitro
by: Alindya Diani, et al.
Published: (2020-02-01)

Risk factors of nosocomial infections caused by piperacillin-tazobactam resistant Pseudomonas aeruginosa
by: Đorđević Zorana, et al.
Published: (2013-01-01)

Impact of piperacillin-tazobactam shortage on meropenem use: implications for antimicrobial stewardship programs
by: Katie E. Barber, et al.
Published: (2016-11-01)

A Case of DRESS Syndrome Associated with Piperacillin-Tazobactam Treatment and Literature Review
by: Seven ULUDOKUMACI, et al.
Published: (2012-12-01)

Synthesis and evaluation of polymeric micelle containing piperacillin/tazobactam for enhanced antibacterial activity
by: Milani Morteza, et al.
Published: (2019-01-01)

Extensive Gene Amplification as a Mechanism for Piperacillin-Tazobactam Resistance in Escherichia coli
by: Lisa M. Schechter, et al.
Published: (2018-04-01)

Efflux Pump AcrAB Confers Decreased Susceptibility to Piperacillin–Tazobactam and Ceftolozane–Tazobactam in Tigecycline-Non-Susceptible Klebsiella pneumoniae
by: Li J, et al.
Published: (2020-11-01)

Outpatient therapy with piperacillin/tazobactam using elastomeric pumps in patients with Pseudomonas aeruginosa infection
by: Jose Luis Lamas Ferreiro, et al.
Published: (2021-04-01)

Characterization of Piperacillin/Tazobactam-Resistant Klebsiella oxytoca Recovered from a Nosocomial Outbreak.
by: Ai Fujita, et al.
Published: (2015-01-01)

Acute Kidney Injury in Pediatric Treated with Vancomycin and Piperacillin-Tazobactam in Tertiary Care Hospital
by: Mohammed Al Nuhait, et al.
Published: (2018-01-01)

Development of Clostridium difficile resistance to Piperacillin/Tazobactam over a period of ten years
by: Ahlund, Veronica
Published: (2017)

Efeito de concentração sub-inibitóra de piperacilina-tazobactam na morfologia e fisiologia de Escherichia coli
by: Joao Paulo Lopes de Andrade
Published: (2010)

Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections
by: Teresa L Kauf, et al.
Published: (2017-04-01)

Integrated Genome-Wide Analysis of an Isogenic Pair of <i>Pseudomonas aeruginosa</i> Clinical Isolates with Differential Antimicrobial Resistance to Ceftolozane/Tazobactam, Ceftazidime/Avibactam, and Piperacillin/Tazobactam
by: Weihua Huang, et al.
Published: (2020-02-01)

Comparing ceftolozane/tazobactam versus piperacillin/tazobactam as empiric therapy for complicated urinary tract infection in Taiwan: A cost-utility model focusing on gram-negative bacteria
by: Guan-Jhou Chen, et al.
Published: (2019-10-01)

RICERCA DI ESßL: SISTEMA VITEK 2 VS ETEST
by: C. Bonetti, et al.
Published: (2003-06-01)

An Investigation of Aspects Affecting Availability and the Health-economical Consequences of Shortages ofVancomycin and Piperacillin/Tazobactam
by: Cederwall, Ida, et al.
Published: (2020)

Evaluating the appropriateness of carbapenem and piperacillin-tazobactam prescribing in a tertiary care hospital in Saudi Arabia
by: Nada A Alsaleh, et al.
Published: (2020-11-01)

Prospective evaluating the appropriate use of piperacillin /tazobactam in cardiac center of a tertiary care hospital
by: Sanaa Saeed Mekdad, et al.
Published: (2020-05-01)

Comparison of the incidence of acute kidney injury during treatment with vancomycin in combination with piperacillin–tazobactam or with meropenem
by: Majed S. Al Yami
Published: (2017-11-01)

Penetration of Piperacillin/Tazobactam Into Gynecologic Tissues Following a Single Loading Dose Prior to Hysterectomy
by: William F. O'Brien, et al.
Published: (1994-01-01)

Study of the Comparative Activity of Piperacillin/Tazobactam with Currently Available Antibiotics against 8206 Aerobic Isolates
by: Kevin R Forward, et al.
Published: (1997-01-01)

Randomized Comparison of Piperacillin/Tazobactam Versus Imipenem/Cilastatin in the Treatment of Patients with Intra-abdominal Infection
by: Alex A. Erasmo
Published: (2004-07-01)

Clinical outcomes with alternative dosing strategies for piperacillin/tazobactam: a systematic review and meta-analysis.
by: Hui Yang, et al.
Published: (2015-01-01)

Third generation cephalosporins and piperacillin/tazobactam have distinct impacts on the microbiota of critically ill patients
by: Hasinika K. A. H. Gamage, et al.
Published: (2021-03-01)

Superinfection rate among the patients treated with carbapenem versus piperacillin/tazobactam: Retrospective observational study
by: Hessa Al Muqati, et al.
Published: (2021-03-01)

A meta-analysis of piperacillin/tazobactam versus cefepime treatment in cancer patients with febrile neutropenia
by: Zhang Weidong, et al.
Published: (2016-12-01)

ACUTE KIDNEY INJURY IN PATIENTS TREATED WITH VANCOMYCIN AND PIPERACILLIN-TAZOBACTAM: A RETROSPECTIVE COHORT ANALYSIS
by: Rutter, Wilbur Cliff
Published: (2016)

Comparison of piperacillin plasma concentrations in a prospective randomised trial of extended infusion versus intermittent bolus of piperacillin/tazobactam in paediatric patients
by: Tatchanapong Chongcharoenyanon, et al.
Published: (2021-07-01)